 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...2021222324252627282930...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Peripapillary choroidal neovascularization related to optic disc drusen treated by ranibizumab: Results at 6 years (Pubmed Central) - Sep 8, 2021
No abstract available
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Anterior Segment Optical Coherence Tomography Angiography Assessment of Corneal Vascularisation After Combined Fine-Needle Diathermy with Subconjunctival Ranibizumab: A Pilot Study. (Pubmed Central) - Sep 8, 2021
No abstract available Combined imaging of SLP and AS-OCTA is useful for monitoring treatment response of corneal scarring and CoNV after combined FND with subconjunctival Ranibizumab.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy (Pubmed Central) - Sep 3, 2021
This retrospective study included 296 eyes of 191 patients (104 male, 87 female) who started intravitreal ranibizumab treatment after being diagnosed with DME in the retina unit between January 2013 and April 2017 were included the study...The coexistence of SD with DME was associated with increased need for treatment but not with final visual acuity. EZ irregularities, DRIL, and ERM are findings that negatively affect visual acuity.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: Cost-minimization Analysis of Ranibizumab versus Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration in Colombia. (Pubmed Central) - Sep 3, 2021
: Within the Colombian healthcare setting anti-VEGF therapy on a T&E regimen utilizing ranibizumab for neovascular ARMD may be cost-saving compared with employing aflibercept. Despite cost favorability, ranibizumab should not be the only therapeutic option since in clinical practice alternatives are required.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration (Pubmed Central) - Sep 3, 2021
All eyes were treated with IV ranibizumab...Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features.
- | Avastin (bevacizumab) / Roche
Journal: Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age related macular degeneration. (Pubmed Central) - Sep 2, 2021
There was no significant difference in VA gains amongst all three drugs but ranibizumab and aflibercept seemed to be more efficacious in quelling disease activity 4 weeks after the first treatment. VA change after the first injection was driven largely by baseline characteristics such as age, baseline VA and lesion size.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. (Pubmed Central) - Sep 2, 2021
Electronic records of treatment-naïve eyes initiated on intravitreal ranibizumab between January and December 2009 were accessed...Patients discontinuing treatment were older and had lower baseline vision compared to completers. VA declined below the baseline after 10 years of follow-up and switching did not have any effect on the final visual outcome.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity (clinicaltrials.gov) - Sep 1, 2021
P3, N=36, Recruiting, Sponsor: Zagazig University
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Real-life data in the treatment of neovascular age-related macular degeneration. Results from the I-maculaweb registry evaluated in a single Italian Medical Retina center. (Pubmed Central) - Sep 1, 2021
VA declined below the baseline after 10 years of follow-up and switching did not have any effect on the final visual outcome. Imaculaweb turned out to be an effective tool to collect and share clinical data as well as to monitor patient outcome.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients. (Pubmed Central) - Sep 1, 2021
One + PRN ranibizumab is safe and efficacious in treatment-naïve patients with ME secondary to BRVO. A conjunctive laser treatment did not lead to better functional outcomes or fewer ranibizumab injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. (Pubmed Central) - Aug 29, 2021
There is no general consensus regarding the use of intravitreal anti-VEGF agents in patients with DR. Although anti-VEGF agents are the gold standard in the treatment of DME and seem to improve DR severity, challenges in their use exist and should be taken into account in the decision of treatment, based on an individualized approach.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: Contrast sensitivity and quality of life following intravitreal ranibizumab injection for central retinal vein occlusion. (Pubmed Central) - Aug 29, 2021
CS had a stronger association with VR-QOL than with BCVA in patients with CRVO-CMO. With the resolution of macular oedema, CS was associated with ELM-RPE thickness and average GCIPL thickness.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Reimbursement, Journal: EFFECT OF REIMBURSEMENT POLICY ON VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH RANIBIZUMAB. (Pubmed Central) - Aug 29, 2021
Health care policy change significantly affected the visual outcomes of patients with diabetic macular edema in a clinical practice setting, with superior final BCVA and BCVA improvement after increased reimbursement. Presence of subretinal fluid at baseline predicted enhanced post-policy change visual improvement.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: CLINICAL OUTCOME OF POLYPOIDAL CHOROIDAL VASCULOPATHY/ANEURYSMAL TYPE 1 NEOVASCULARIZATION ACCORDING TO CHOROIDAL VASCULAR MORPHOLOGY. (Pubmed Central) - Aug 29, 2021
Presence of subretinal fluid at baseline predicted enhanced post-policy change visual improvement. The polypoidal choroidal vasculopathy/aneurysmal Type 1 eyes with a diffuse pattern of pachyvessels required fewer injections during 12-month follow-up and showed a longer injection-free period after rescue photodynamic therapy.
- || Avastin (bevacizumab) / Roche
Clinical, Review, Journal: Review of Ophthalmic and Breastfeeding Medicine Evidence: Real and Theoretical Risks of Intravitreal Anti-VEGF Administration in Lactating Women. (Pubmed Central) - Aug 29, 2021
However, there is significant need for further research on the degree and duration to which intravitreal agents circulate systemically, what fraction is transferred into breastmilk and is absorbed, and whether this results in any functional adverse effects to the infant. Other factors to consider in the medical decision-making of lactating mothers necessitating intravitreal anti-VEGF treatment include the gestational and post-natal age of the child and whether it is feasible to avoid breastfeeding for the half-life duration of the intravitreal agent rather than ceasing breastfeeding altogether.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. (Pubmed Central) - Aug 28, 2021
Ranibizumab was preferred as an initial treatment agent in older patients and those with type 3 MNV, whereas aflibercept was highly preferred in patients with PCV. The different characteristics and efficacy of the two agents may have partially contributed to this trend.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The effect of intravitreally administered angiogenesis inhibitor on the concentration of angiotensin-converting enzyme in the blood serum and lacrimal fluid in patients with diabetic macular edema (Pubmed Central) - Aug 27, 2021
Similar changes that were observed after IVI of ranibizumab in patients with AMD confirm the mutual influence of these two systems. The data presented in this study open up prospects for finding new pathways of pathogenic therapy for diabetic macular edema and diabetes.
- | Avastin (bevacizumab) / Roche
Journal: Using different proteolytic enzymes to digest antibody and its impact on stability of antibody mimetics. (Pubmed Central) - Aug 27, 2021
Interestingly, the FpF mimetics prepared from the homogenous Fabs (Fab and Fab), displayed greater stability compared to their starting bevacizumab and ranibizumab after being lyophilised as determined by DLS analysis. There is a potential to lyophilize FpFs to be used to fabricate solid-state depots.
- | Lucentis (ranibizumab) / Roche, Novartis
Observational data, Journal: Aniseikonia following intravitreal ranibizumab treatment for branch retinal vein occlusion. (Pubmed Central) - Aug 27, 2021
The BCVA as well as the micropsia improved following treatment with IVR for BRVO. BCVA and the presence of SRD were predictors of post-treatment aniseikonia.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. (Pubmed Central) - Aug 26, 2021
Most patients will be classified as complete responders if intervals less than 4 weeks are used to assess anti-VEGF treatment response. Disease load rather than eye size appears to be the driver of anti-VEGF treatment duration and therefore, dosing interval needs to be optimized in the cohort of short-term responders.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema. (Pubmed Central) - Aug 26, 2021
Disease load rather than eye size appears to be the driver of anti-VEGF treatment duration and therefore, dosing interval needs to be optimized in the cohort of short-term responders. Our findings suggest that the change in aqueous humor levels of VEGF, PlGF, and ICAM-1 in DME may not only be an anatomic response but also a potential therapeutic target.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficiency of Intravitreal Ranibizumab in Choroidal Neovascularization: Monthly versus Pro Re Nata versus Treat and Extend Protocol () - Aug 25, 2021 - Abstract #APAO2021APAO_1389;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficiency of Intravitreal Ranibizumab in Retinal Vein Occlusion: Monthly vs Pro Re Nata vs Treat and Extend Protocol () - Aug 25, 2021 - Abstract #APAO2021APAO_1386;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficiency of Intravitreal Ranibizumab in Diabetic Retinopathy: Monthly vs Pro Re Nata vs Treat and Extend () - Aug 25, 2021 - Abstract #APAO2021APAO_1330;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Bilateral Isolated Sixth Cranial Nerve Palsy after Intravitreal Ranibizumab Injection: A Rare Complication () - Aug 25, 2021 - Abstract #APAO2021APAO_1328;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Reduced Expression of Erythropoietin after Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients () - Aug 25, 2021 - Abstract #APAO2021APAO_1325;
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: Association Between Intravitreal Aflibercept and Serious Non-ocular Haemorrhage Compared with Intravitreal Ranibizumab: A Multicentre Observational Cohort Study. (Pubmed Central) - Aug 25, 2021
No association was identified between intravitreal aflibercept and non-ocular haemorrhage versus ranibizumab. A comparable risk for these intravitreal anti-VEGFs and intravitreal dexamethasone was observed.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Short-Term Outcomes following "Switching" to Monthly Ranibizumab in Neovascular Age-Related Macular Degeneration Showing Insufficient Response to Bimonthly Aflibercept. (Pubmed Central) - Aug 24, 2021
Switching to monthly ranibizumab in nAMD showing an insufficient response to bimonthly aflibercept led to immediate anatomical improvement. It can be considered in countries where the healthcare insurance system limits the minimum injection interval of aflibercept.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Optical quality assessment in branch retinal vein occlusion after monthly intravitreal ranibizumab injection: a prospective, case-control study. (Pubmed Central) - Aug 22, 2021
BRVO resulted in declined visual acuity and optical quality. It is suggested that the optical quality parameters are affected by the inner layers of the retina in BRVO.
- | Avastin (bevacizumab) / Roche
Journal: Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy. (Pubmed Central) - Aug 21, 2021
Our study revealed that optical coherence tomography angiography can be used noninvasively and quantitatively to assess the detailed pathologic vascular structures in both neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Our study also demonstrated that anti-vascular endothelial growth factor could effectively decrease the lesion size and flow area of both the choroidal neovascularization in neovascular age-related macular degeneration cases and the polypoidal complex in polypoidal choroidal vasculopathy cases; the effects were similar in both diseases.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab. (Pubmed Central) - Aug 21, 2021
Our study also demonstrated that anti-vascular endothelial growth factor could effectively decrease the lesion size and flow area of both the choroidal neovascularization in neovascular age-related macular degeneration cases and the polypoidal complex in polypoidal choroidal vasculopathy cases; the effects were similar in both diseases. There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD. (Pubmed Central) - Aug 21, 2021
SNP profile of High Responders (HR) was also compared with Low Responders (LR) to ranibizumab...APOE rs4420638 (A/G) was the single SNP more frequently linked to vPED eyes for both comparisons. FRK rs3812111 (T/A) was consistently associated with high responders.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect. (Pubmed Central) - Aug 21, 2021
IVR conforms to the previously described regression patterns following intravitreal bevacizumab for ROP indicative of a class effect. Follow-up using FA might help to optimize the management of these infants after injection of the drug.
- || Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: Systematic review and meta-analysis. (Pubmed Central) - Aug 21, 2021
The need for rescue laser was similar the two groups. Intravitreal RNB was more effective with less pronounced effect on IOP and cataract formation and/or progression compared to DII for patients with macular edema secondary to BRVO.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR: Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population. (Pubmed Central) - Aug 20, 2021
The results demonstrated that a subject has to pay 20.951 times more cost (in INR) for RBZ+laser therapy compared to BVZ+laser therapy, to get an almost similar outcome. BVZ is found to be the more attractive option for treating DME in DR for its cost-friendliness over RBZ in terms of BCVA outcome, as well as the safety perspectives, at least for the economically backward population in developing countries, like India.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles. (Pubmed Central) - Aug 20, 2021
Our results demonstrate that bioreducible lipidoid nanoparticles conveying VEGF siRNA can effectively inhibit retinal neovascularization in a rodent model of OIR, and reduce the expression of VEGF mRNA and protein. This novel treatment modality could have profound implications for treating retinal angiogenic diseases.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration. (Pubmed Central) - Aug 20, 2021
This novel treatment modality could have profound implications for treating retinal angiogenic diseases. The extent of damage to the EZ and ELM correlates with BCVA following a switch in treatment.
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis
Journal: One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. (Pubmed Central) - Aug 20, 2021
There were no clear differences between combination therapy of anti-VEGF with STTA and anti-VEGF monotherapy for the treatment of patients with ME associated with BRVO. The number of anti-VEGF injections in patients who received the combination therapy was not reduced as compared with the number of anti-VEGF injections in patients who received the monotherapy.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Monotherapy, Real-world evidence: Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia. (Pubmed Central) - Aug 20, 2021
Anti-VEGF agents can be successfully used to treat proliferative MacTels. Macular volume measurement on OCT may be a useful parameter for evaluating EF-SRNVM and as a prognostic marker of management outcomes.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. (Pubmed Central) - Aug 20, 2021
Similar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment. (Pubmed Central) - Aug 20, 2021
Moreover, slower CRT changes may occur over the years, either decrease or increase. In case of a slow CRT increase, this might require a diagnostic workup and therapeutic change.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. (Pubmed Central) - Aug 20, 2021
These findings suggest a beneficial effect of switching from ranibizumab to aflibercept in eyes with ongoing chronic anti-VEGF treatment irrespective of previous response to ranibizumab. Longer follow-up is required to further evaluate the potential clinical significance of this finding.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Retinal venous pressure is decreased after anti-VEGF therapy in patients with retinal vein occlusion-related macular edema. (Pubmed Central) - Aug 20, 2021
The anti-VEGF treatment resulted in a significant decrease in the RVP, but the RVP remained significantly higher than the IOP. An increased RVP plays a decisive role in the formation of macula edema, and reducing it is desirable.
- | Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. (Pubmed Central) - Aug 20, 2021
The portion of eyes achieving disease stability regressed in the second year, whereas the portion of eyes under a ≥ 12-week interval increased. This discrepancy may reflect the challenges in balancing between under-treatment and a reduced treatment burden.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Risk factors for fellow eye treatment in protocol T. (Pubmed Central) - Aug 20, 2021
This discrepancy may reflect the challenges in balancing between under-treatment and a reduced treatment burden. Bilateral treatment with intravitreal anti-VEGF injections was common during the DRCR.net Protocol T. Medication choice may impact the risk of fellow eye treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years (Pubmed Central) - Aug 20, 2021
Bilateral treatment with intravitreal anti-VEGF injections was common during the DRCR.net Protocol T. Medication choice may impact the risk of fellow eye treatment. Recurrences times are not reproducible over follow-up, particularly in patients experience their first exudative recurrence beyond 8 weeks and in patients with multiple exudative recurrences.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial. (Pubmed Central) - Aug 19, 2021
LQHB plus intravitreal ranibizumab could be a much more effective and economic treatment for stabilizing and improving vision with fewer intravitreal injections in the treatment of RVO induced ME. This integrative therapy appears to be a promising option for this type of patient.
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Aug 18, 2021
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
This integrative therapy appears to be a promising option for this type of patient. Trial primary completion date: Dec 2022 --> Jul 2022
- |||| Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
Trial primary completion date: XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) - Aug 18, 2021
P3, N=580, Active, not recruiting, Sponsor: Xbrane Biopharma AB
Trial primary completion date: Dec 2022 --> Jul 2022 Trial primary completion date: Dec 2021 --> May 2021
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion date, Trial primary completion date, Monotherapy: Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) - Aug 18, 2021
P4, N=150, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Dec 2021 --> May 2021 Trial completion date: Nov 2021 --> Feb 2022 | Trial primary completion date: Aug 2021 --> Nov 2021